Related references
Note: Only part of the references are listed.Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
Mingjie Zhang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient
Banchob Sripa et al.
HUMAN CELL (2020)
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
Jialin Qu et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Regulation of PD-1 in T cells for cancer immunotherapy
Xibao Yu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Jiangang Sun et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Roles of IFN-γ in tumor progression and regression: a review
Dragica Jorgovanovic et al.
BIOMARKER RESEARCH (2020)
Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection
Magnus Rizell et al.
CASE REPORTS IN ONCOLOGY (2020)
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Christian Bailly et al.
NAR CANCER (2020)
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
Neda Yaghoubi et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Effect of pembrolizumab on CD4+CD25+, CD4+LAP+ and CD4+TIM-3+ T cell subsets
S. M. Toor et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)
Hepatobiliary and Pancreatic: Biliary injury related to checkpoint inhibitor pembrolizumab
A. Kida et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1
Jing Xue et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis
Gang Xu et al.
FRONTIERS IN ONCOLOGY (2019)
Cyclooxygenase-2 in cancer: A review
Nasser Hashemi Goradel et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer
Katsuhiko Shimizu et al.
ANTICANCER RESEARCH (2018)
Combined checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer
Mamta Parikh et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
In-vitro effect of pembrolizumab on different T regulatory cell subsets
S. M. Toor et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2018)
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
Gerardo Botti et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
Jacqueline Fontugne et al.
ONCOTARGET (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management
Irai S. Oliveira et al.
ABDOMINAL RADIOLOGY (2017)
Epidemiology and risk factors: intrahepatic cholangiocarcinoma
Amar Gupta et al.
HEPATOBILIARY SURGERY AND NUTRITION (2017)
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Francesco Sabbatino et al.
CLINICAL CANCER RESEARCH (2016)
Upregulation of 14-3-3 eta in chronic liver fluke infection is a potential diagnostic marker of cholangiocarcinoma
Ornuma Haonon et al.
PROTEOMICS CLINICAL APPLICATIONS (2016)
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Faiz Gani et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
Masaki Mandai et al.
CLINICAL CANCER RESEARCH (2016)
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino et al.
DRUGS (2016)
Establishment and characterization of a novel human cholangiocarcinoma cell line with high metastatic activity
Kwuntida Uthaisar et al.
ONCOLOGY REPORTS (2016)
Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma
Lei Wang et al.
ONCOTARGET (2016)
IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells
Z. Sun et al.
CANCER RESEARCH (2015)
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Santiago Zelenay et al.
CELL (2015)
Expression of COX-2 and VEGF-C in cholangiocarcinomas at different clinical and pathological stages
Z. You et al.
GENETICS AND MOLECULAR RESEARCH (2015)
Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection
Jonathan H. Chen et al.
NATURE MEDICINE (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillance by Enhancing Intratumoral Immune Checkpoint Activity
Nune Markosyan et al.
BREAST CANCER RESEARCH (2013)
Immunodetection of cyclooxygenase-2 (COX-2) is restricted to tissue macrophages in normal rat liver and to recruited mononuclear phagocytes in liver injury and cholangiocarcinoma
Marta Wojcik et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2012)
Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway
Jiao Chen et al.
IMMUNOBIOLOGY (2012)
Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma
Sumalee Obchoei et al.
MOLECULAR CANCER (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Interaction of B7-H1 on Intrahepatic Cholangiocarcinoma Cells With PD-1 on Tumor-Infiltrating T Cells as a Mechanism of Immune Evasion
Yufu Ye et al.
JOURNAL OF SURGICAL ONCOLOGY (2009)
Microenvironmental regulation of metastasis
Johanna A. Joyce et al.
NATURE REVIEWS CANCER (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Surgical resection of hilar cholangiocarcinoma: Analysis of survival and postoperative complications
Suguru Hasegawa et al.
WORLD JOURNAL OF SURGERY (2007)
Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient
Panthip Rattanasinganchan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)
Banchob Sripa et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Expression of cyclooxygenase-2 in cholangiocarcinoma: Correlation with clinicopathological features and prognosis
HJ Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT
M Maruyama et al.
TRANSPLANTATION (2004)
Cyclooxygenase-2 promotes human cholangiocarcinoma growth:: Evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21Waf1/cip1 and p27kip1 and cell cycle arrest
C Han et al.
CANCER RESEARCH (2004)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions
K Endo et al.
HEPATOLOGY (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm
N Hayashi et al.
HEPATOLOGY (2001)
Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma
S Chariyalertsak et al.
GUT (2001)
Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis
A Rullier et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2000)
Share Paper
